Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 16 of the 67 sources its claims cite were checked for support.

Atopic dermatitis

Open access
Kapur, Sandeep, Watson, Wade, Carr, Stuart · 2018 · Allergy, Asthma & Clinical Immunology

Abstract

Atopic dermatitis (AD) is a common, chronic skin disorder that can significantly impact the quality of life of affected individuals as well as their families. Although the pathogenesis of the disorder is not completely understood, it appears to result from the complex interplay between defects in skin barrier function, environmental and infectious agents, and immune dysregulation. There are no diagnostic tests for AD; therefore, the diagnosis is based on specific clinical criteria that take into account the patient's history and clinical manifestations. Successful management of the disorder requires a multifaceted approach that involves education, optimal skin care practices, anti-inflammatory treatment with topical corticosteroids and/or topical calcineurin inhibitors, the management of pruritus, and the treatment of skin infections. Systemic immunosuppressive agents may also be used, but are generally reserved for severe flare-ups or more difficult-to-control disease. Topical corticosteroids are the first-line pharmacologic treatments for AD, and evidence suggests that these agents may also be beneficial for the prophylaxis of disease flare-ups. Although the prognosis for patients with AD is generally favourable, those patients with severe, widespread disease and concomitant atopic conditions, such as asthma and allergic rhinitis, are likely to experience poorer outcomes.

Overview

CoChat Summary

TL;DR

Atopic dermatitis (AD) is a common chronic pruritic skin disorder driven by skin barrier defects, immune dysregulation, and environmental/infectious factors, with diagnosis based on clinical criteria rather than specific tests. Management centers on education, skin care, topical corticosteroids, and topical calcineurin inhibitors, with systemic agents reserved for severe or refractory disease.

Key findings

  • AD affects an estimated 10–20% of children and 1–3% of adults in developed countries; approximately 45% of cases begin within the first 6 months of life, 60% during the first year, and 85% before 5 years of age, while up to 70% of children enter clinical remission before adolescence.
  • The annual cost of AD in Canada is estimated at $1.4 billion; *S. aureus* colonizes approximately 90% of AD patients, and early consistent emollient use in at-risk infants has been associated with a 30–50% reduction in AD diagnosis at 6 months.
  • About 35% of children with moderate-to-severe AD have contributory food allergies, but random food-allergen screening is not recommended because positive predictive value can be as low as 2%; allergy testing should be guided by history.
  • Topical corticosteroids are first-line pharmacologic treatment and may also help prevent flares; TCIs are second-line, and dupilumab has been approved in Canada for moderate-to-severe AD not adequately controlled with topical therapies, with two phase 3 trials showing significant symptom and quality-of-life improvement versus placebo.

Methods

  • Narrative review/overview of current literature on the epidemiology, pathophysiology, diagnosis, and management of atopic dermatitis.
  • No primary data collection, systematic search strategy, or meta-analysis is described; the article synthesizes cited studies, guidelines, and trials.
  • Main analysis is a narrative synthesis of diagnostic criteria, allergy assessment, prevention, and stepwise treatment approaches.

Limitations

  • The paper states that AD pathogenesis is not completely understood; the exact role of foods and aeroallergens in AD is controversial; there is limited clinical trial data to guide corticosteroid selection; long-term UV phototherapy toxicity is unknown; and a systematic review found no good-quality evidence that wet-wrap therapy is superior to conventional topical corticosteroids.
  • Evident from the text: as a narrative review, it does not report a systematic search strategy, inclusion/exclusion criteria, or formal quality appraisal of cited evidence.
  • Evident from the text: recommendations rely on synthesis of existing literature and expert opinion rather than primary data, and potential publication or selection bias is not addressed.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13223-018-0281-6

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 AD of the flexural surfaces of the extremities
Fig. 1 AD of the flexural surfaces of the extremitiesCC BY · PubMed Central
Fig. 2 AD of the hands (a) and feet (b)
Fig. 2 AD of the hands (a) and feet (b)CC BY · PubMed Central
Fig. 3 A simplified, stepwise algorithm for the treatment of AD
Fig. 3 A simplified, stepwise algorithm for the treatment of ADCC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 0 Not valid · 25 Not checked · 2 Own results and interpretations

15 more claims · 3 with their cited sources checked

Create a free account to see all 41 claims and to verify the 6 references still open.

See all claims — free account
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • Probably not a substantial claim. 8
  • It may state two separate claims as one. 18

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Self-check results appear here once an independent check has confirmed them.

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

2 of 2

Citations

Cites

2 retracted

Show all 39 references

Cited by

See all 175

Metadata

Authors
Kapur, S., Watson, W., & Carr, S.
Affiliations
  • Dalhousie University (CA)
  • University of Alberta (CA)
Corresponding author
Kapur, Sandeep
Venue
Allergy, Asthma & Clinical Immunology
Published
2018-09
Volume
14
Issue
S2
Pages
52-52
ISSN
  • 1710-1484 (ISSN-L)
  • 1710-1492
OpenAlex
W4255155429
Cited by
175
References
39
Citations by year
2026: 12 · 2025: 22 · 2024: 33 · 2023: 31 · 2022: 17 · 2021: 31 · 2020: 18 · 2019: 9 · 2018: 1
FWCI
2.37
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Allergy Asthma and Clinical Immunology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Pfizer
  • AstraZeneca
  • Teva Pharmaceutical Industries
  • CSL Behring
  • Merck Canada
  • Pfizer Canada
  • Takeda Canada
  • Shire Canada
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
atopic dermatitis, skin barrier dysfunction, immune dysregulation, diagnosis, topical corticosteroids, calcineurin inhibitors, pruritus management, skin infections, systemic immunosuppressive therapy, disease flares, prognosis, asthma, allergic rhinitis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Atopic dermatitis. https://app.cochat.ai/papers/10.1186/s13223-018-0281-6
The paper
Kapur, S., Watson, W., & Carr, S. (2018). Atopic dermatitis. Allergy, Asthma & Clinical Immunology. https://doi.org/10.1186/s13223-018-0281-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.